Skip to main content

Table 3 Cure rates (CR), extended CRs, egg-reduction rates (ERR), extended ERRs and reinfection data for the four different treatments against hookworms infections. Results of baseline and 3 weeks follow-up have been reported elsewhere [13]

From: Efficacy and reinfection with soil-transmitted helminths 18-weeks post-treatment with albendazole-ivermectin, albendazole-mebendazole, albendazole-oxantel pamoate and mebendazole

Hookworms

 

Weeks post-treatment

Albendazole – ivermectin (n = 100)

Albendazole – mebendazole (n = 101)

Albendazole – oxantel pamoate (n = 100)

Mebendazole (n = 104)

Children positive before treatment (%)

38 (38.0)

43 (42.6)

50 (50.0)

41 (39.4)

No. of children cured (CR, 95 % CI)

3 weeks

17 (44.7, 28.6–61.7)

21 (48.8, 33.3–64.5, p = 0.022)*

24 (48.0, 33.7–62.6, p = 0.023)*

10 (24.4, 12.4–40.3)

No. of children negative (extended CR, 95 % CI)

18 weeks

19 (50.0, 33.4–66.6)

23 (53.5, 37.7–68.8)

27 (54.0, 39.3–68.2)

14 (34.2, 20.1–50.6)

Geometric mean: EPG

Baseline

113.1

139.8

87.2

80.0

3 weeks

6.1

8.3

7.1

31.8

18 weeks

6.3

6.3

6.6

20.7

ERR (95 % CI)

3 weeks

94.6 (89.2–97.6)a

94.1 (88.7–97.0)a

91.9 (85.0–95.8)a

60.3 (27.8–79.2)

Extended ERR (95 % CI)

18 weeks

94.4 (88.8–97.5)a

95.5 (91.5–97.8)a

92.4 (85.4–96.3)

74.1 (52.8–86.4)

No. of children positive (prevalence, 95 % CI)

Baseline

38 (38.0, 28.3–47.7)

43 (42.6, 32.8–52.4)

50 (50.0, 40.0–60.0)

41 (39.4, 29.9–49.0)

3 weeks

26 (26.0, 17.3–34.7)

26 (25.7, 17.1–34.4)

31 (31.0, 21.8–40.2)

44 (42.3, 32.7–52.0)

18 weeks

27 (27.0, 18.1–35.9)

32 (31.7, 22.5–40.9)

34 (34.0, 24.6–43.4)

39 (37.5, 28.0–47.0)

Reinfections (%, 95 % CI)

18 weeks

5/17 (29.4, 10.3–56.0)

4/21 (19.0, .4–41.9)

6/24 (25.0, 9.8–46.7)

3/10 (30.0, 6.7–65.4)

New infections (%, 95 % CI)

18 weeks

6/57 (10.5, 4.0–21.5)

9/54 (16.7, 7.9–29.3)

8/45 (17.8, 8.0–32.1)

6/50 (12.0, 4.5–24.3)

  1. Data are n (%, 95 % CI) unless otherwise indicated. EPG = egg per gram of stool
  2. *Significantly higher CR compared to mebendazole (P-values derived from logistic regression)
  3. aSignificantly higher ERR compared to mebendazole (no overlapping confidence interval assumption)